A novel nonsecosteroidal VDR agonist (CH5036249) exhibits efficacy in a spontaneous benign prostatic hyperplasia beagle model.
Taniguchi
K
K
Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura Research Labs., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan. taniguchiknj@chugai-pharm.co.jp
Katagiri
K
K
Kashiwagi
H
H
Harada
S
S
Sugimoto
Y
Y
Shimizu
Y
Y
Arakawa
H
H
Ito
T
T
Yamazaki
M
M
Watanabe
T
T
Kato
A
A
Hoshino
E
E
Takahashi
T
T
Esaki
T
T
Suzuki
M
M
Takeda
S
S
Ichikawa
F
F
Harada
A
A
Sekiguchi
N
N
Ishigai
M
M
Kawata
H
H
Yoneya
T
T
Onuma
E
E
Sudoh
M
M
Aoki
Y
Y
D000818:Animals; D001559:Benzhydryl Compounds / Q000737:chemistry / Q000494:pharmacology*; D002118:Calcium / Q000097:blood; D049109:Cell Proliferation; D004195:Disease Models, Animal; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D015162:Micronucleus Tests; D008954:Models, Biological; D011467:Prostate / Q000187:drug effects / Q000378:metabolism; D011470:Prostatic Hyperplasia / Q000473:pathology*; D011725:Pyridines / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D018167:Receptors, Calcitriol / Q000819:agonists* / Q000378:metabolism; D017154:Stromal Cells / Q000166:cytology
D001559:Benzhydryl Compounds; C552205:CH 5036249; D011725:Pyridines; D018167:Receptors, Calcitriol; D002118:Calcium